拉考沙胺辅助治疗难治性睡眠相关运动性癫痫（以前称为夜间额叶癫痫）的病例系列。
A case series of lacosamide as adjunctive therapy in refractory sleep-related hypermotor epilepsy (previously nocturnal frontal lobe epilepsy).
机构信息
Epilepsy Research Centre, Department of Medicine, University of Melbourne, Melbourne, Vic., Australia.
Department of Paediatrics, University of Melbourne, Melbourne, Vic., Australia.
出版信息
J Sleep Res. 2018 Oct;27(5):e12669. doi: 10.1111/jsr.12669. Epub 2018 Feb 25.
The aim of this study was to evaluate the efficacy and tolerability of open-label lacosamide in patients with refractory sleep-related hypermotor epilepsy. The study was a case review of eight patients with refractory sleep-related hypermotor epilepsy treated with lacosamide. Seizure diaries compared the mean baseline seizure frequency with the most recent 3 months of follow-up. Five (62.5%) patients were responders, defined as ≥50% reduction in seizure frequency, over a mean duration of exposure of 21.5 months. The mean maintenance dose of lacosamide was 400 mg/day. No-one reported worsening of seizures. Lacosamide was well tolerated with initial fatigue being the main side-effect. Lacosamide is a potentially efficacious adjunctive therapy in patients with refractory sleep-related hypermotor epilepsy. A double-blind placebo-controlled study would determine its efficacy.
本研究旨在评估开放标签拉考沙胺治疗难治性睡眠相关运动性癫痫的疗效和耐受性。该研究为回顾性病例研究，纳入了 8 例接受拉考沙胺治疗的难治性睡眠相关运动性癫痫患者。通过比较癫痫日记，评估了患者基线期平均癫痫发作频率与最近 3 个月随访期间的情况。5 例（62.5%）患者为应答者，即癫痫发作频率降低≥50%，平均暴露时间为 21.5 个月。拉考沙胺的平均维持剂量为 400mg/天。无人报告癫痫发作恶化。拉考沙胺耐受性良好，初始时的疲劳是主要副作用。拉考沙胺可能是治疗难治性睡眠相关运动性癫痫的有效辅助治疗药物。一项双盲安慰剂对照研究将确定其疗效。
Zotero 插件